Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ZBIO Zenas BioPharma Inc.

Post-Mkt 06-22 17:30:11 EDT

20.80

+1.02

+5.16%

盘后20.80

+0.000.00%

16:10 EDT

High20.97	Low19.99	Vol643.18K
Open20.20	D1 Closing19.78	Amplitude4.95%
Mkt Cap1.31B	Tradable Cap828.71M	Total Shares63.13M
T/O13.26M	T/O Rate1.61%	Tradable Shares39.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":20.8,"timestamp":1782158400000,"preClose":19.78,"halted":0,"volume":643181,"hourTrading":{"tag":"盘后","latestPrice":20.8,"preClose":20.8,"latestTime":"16:10 EDT","volume":12635,"amount":262808,"timestamp":1782159005308,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.05156723963599593,"floatShares":39841600,"shares":63133400,"eps":-8.823121,"marketStatus":"Post-Mkt","change":1.02,"latestTime":"06-22 17:30:11 EDT","open":20.2,"high":20.97,"low":19.99,"amount":13258030,"amplitude":0.049545,"askPrice":20.99,"askSize":20,"bidPrice":18.03,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-8.823121,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1782172800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":19.78,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":20.25,"preClose":19.78,"latestTime":"09:29 EDT","volume":1730,"amount":34813.40934,"timestamp":1782134999999,"change":0.47,"changeRate":0.023761,"amplitude":0.052578},"postHourTrading":{"tag":"盘后","latestPrice":20.8,"preClose":20.8,"latestTime":"16:10 EDT","volume":12635,"amount":262808,"timestamp":1782159005308,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.648687,"impliedVol":0.8091,"impliedVolPercentile":0.3217},"requestUrl":"/m/hq/s/ZBIO/tweets","defaultTab":"tweets","newsList":[{"id":"2644297997","title":"Zenas BioPharma grants 100,000 stock options, 78,075 RSUs to new hires under 2026 inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2644297997","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644297997?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727324,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted inducement equity awards dated June 15, 2026 to newly hired employees: stock options for 100,000 shares, RSUs for 78,075 shares.Options carry a 10-year term, $18.71 exercise price, vesting over four years with 25% after one year, then monthly installments.RSUs vest in four equal tranches on June 15 of 2027 through 2030, subject to continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL2XCDyW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","ZBIO","BK4139","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4588","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","SG9999014005.SGD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644172922","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644172922","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644172922?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nTUAJ4RVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644942721","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2644942721","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644942721?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., June  17, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/17/3313812/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642023120","title":"Zenas BioPharma to present at H.C. Wainwright Neuro Perspectives Expert Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2642023120","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642023120?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:16","pubTimestamp":1781208970,"startTime":"0","endTime":"0","summary":"Zenas BioPharma management to present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL2gc40m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","ZBIO","LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","BK4139","LU0314104364.USD","BK4588","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BKPKM429.USD","NDAQ","LU2095319765.USD","SG9999014021.USD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642280342","title":"Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642280342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642280342?lang=en_us&edition=fundamental","pubTime":"2026-06-11 21:40","pubTimestamp":1781185212,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (Z...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alpha-cognition-inc-acog-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-alpha-cognition-inc-acog-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACOG","ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641480868","title":"A Look At Zenas BioPharma (ZBIO) Valuation After Positive Obexelimab Phase 3 Data And FDA BLA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2641480868","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641480868?lang=en_us&edition=fundamental","pubTime":"2026-06-08 21:28","pubTimestamp":1780925285,"startTime":"0","endTime":"0","summary":"Clinical data and regulatory milestones in focus\nZenas BioPharma (ZBIO) stock is drawing attention after the company reported detailed Phase 3 INDIGO data for obexelimab in IgG4-Related Disease and advanced a Biologics License Application with the FDA.\nSee our latest analysis for Zenas BioPharma.\nDespite the positive INDIGO data and recent Biologics License Application filing, Zenas BioPharma's share price has come under pressure, with the stock down 11.05% over 30 days and 49.36% year to...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-positive-obex","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/a-look-at-zenas-biopharma-zbio-valuation-after-positive-obex","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","LABU","ZBIO","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640021949","title":"Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday Amid Fresh Economic Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2640021949","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640021949?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:10","pubTimestamp":1780492243,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.5% in Wednesday's premarket activity, as markets traded mixe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLI","VIS","XLP","IBB","IYJ","IGM","IYW","UNG","IYH","USO","VHT.AU","RTH","RTH.AU","ZBIO","PMR","SOXX","XRT","VHT","EETH","VDC","XSD","BITO","IVV","XLK","IYE","FDN","SPY","XLE","EEM","GLD","IGV","BETH","XLY","BP","FAZ","BX","IYK","CXM.AU","XLV",".IXIC","CXM","FAS","TE","SPY.AU","RACE","SLV","XLF","QQQ","EQR","IWM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640553977","title":"Zenas BioPharma's Potential Autoimmune Disease Treatment Meets Primary, Secondary Endpoints in Phase 3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640553977","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640553977?lang=en_us&edition=fundamental","pubTime":"2026-06-03 16:41","pubTimestamp":1780476109,"startTime":"0","endTime":"0","summary":"Zenas BioPharma's (ZBIO) obexelimab met all primary and secondary endpoints with \"statistically significant\" results in a phase 3 study in patients with immunoglobulin G4-related disease, the company ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640606921","title":"Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2640606921","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640606921?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:18","pubTimestamp":1780442336,"startTime":"0","endTime":"0","summary":"June 2 (Reuters) - Zenas Biopharma Inc ::*ZENAS BIOPHARMA ANNOUNCES DATA FROM THE REGISTRATIONAL PHASE 3 INDIGO TRIAL OF OBEXELIMAB IN IMMUNOGLOBULIN G4-RELATED DISEASE (IGG4-RD), SIMULTANEOUSLY PRESE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nRSD3qpDrF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921667","title":"Zenas Biopharma posts corporate presentation on autoimmune disease drug pipeline, led by obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921667","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921667?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:12","pubTimestamp":1780441950,"startTime":"0","endTime":"0","summary":"Zenas Biopharma outlined plans to transition to a commercial-stage autoimmune company, citing cash runway into 2029.INDIGO Phase 3 IgG4-RD met the primary endpoint; flare risk reduced 56% vs placebo, HR 0.41; 73% flare-free at week 52.Pipeline focus spans obexelimab, orelabrutinib, ZB021; clinical catalysts include SunStone Phase 2 SLE topline in Q4 2026.Zenas targets potential approvals for three franchise molecules across five I&I indications by 2031; markets estimated at more than $50 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL5LBKvv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921521","title":"Zenas BioPharma says Phase 3 INDIGO trial meets primary endpoint for obexelimab in IgG4-related disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921521","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921521?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441518,"startTime":"0","endTime":"0","summary":"Zenas BioPharma reported additional positive Phase 3 INDIGO results for obexelimab in IgG4-related disease, presented at EULAR 2026 and published in NEJM.The registrational study met its primary endpoint and key secondary endpoints, showing lower disease activity and fewer flares versus placebo.Obexelimab reduced overall steroid use, supporting a steroid-sparing profile with fewer glucocorticoid-related toxicities.Safety was comparable to placebo, strengthening the drug’s risk-benefit profile ahead of potential commercialization.A Biologics License Application for IgG4-related disease was submitted to the FDA in May, setting up a near-term regulatory catalyst.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2lKBtB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4139","SG9999014021.USD","ZBIO","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","BK4112","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921597","title":"Zenas Biopharma Announces Data From the Registrational Phase 3 Indigo Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd), Simultaneously Presented at the Eular 2026 Congress and Published in the New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921597?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921549","title":"Zenas Biopharma - Obexelimab Significantly Lowers Glucocorticoid Use and Toxicities in Indigo Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921549?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921511","title":"Zenas Biopharma - Phase 3 Indigo Trial of Obexelimab Meets Primary and All Key Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921511?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA6N8J1T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921618","title":"Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921618","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921618?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":"- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucoc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305741/0/en/Zenas-BioPharma-Announces-Data-from-the-Registrational-Phase-3-INDIGO-Trial-of-Obexelimab-in-Immunoglobulin-G4-Related-Disease-IgG4-RD-Simultaneously-Presented-at-the-EULAR-2026-Co.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601567","title":"Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601567","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639601567?lang=en_us&edition=fundamental","pubTime":"2026-05-31 00:08","pubTimestamp":1780157299,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO), a clinical-stage immunology specialist, continues to attract attention after a year in which the stock’s total return is reported at 93.28%, contrasting with a year-to-date decline of 46.67%.\nSee our latest analysis for Zenas BioPharma.\nAt the latest share price of $18.40, Zenas BioPharma’s recent 7 day and 90 day share price returns show declines, yet its 1 year total shareholder return of 93.28% still points to earlier gains, indicating that momentum has faded...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/assessing-zenas-biopharma-zbio-valuation-after-a-strong-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/assessing-zenas-biopharma-zbio-valuation-after-a-strong-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698263","title":"Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698263","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698263?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:07","pubTimestamp":1779970036,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  said Thursday it submitted a biologics license application to the US Food and Drug Administration for obexelimab in immunoglobulin G4-related disease, a chronic fibro-inflammatory disease affecting multiple organ systems.Obexelimab is an investigational bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb to inhibit B cell function, the company said.The application is based on results from a phase 3 registrational trial that showed a 56% reduction in the risk of IgG4-RD flare compared with placebo during the 52-week randomized placebo-controlled period, according to the company.Shares of Zenas BioPharma were up more than 1% pre-bell Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638466067","title":"Zenas BioPharma submits FDA BLA for obexelimab in IgG4-related disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638466067","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638466067?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:22","pubTimestamp":1779967354,"startTime":"0","endTime":"0","summary":"Zenas BioPharma submitted a BLA to the FDA seeking approval of obexelimab for IgG4-related disease.Filing backed by Phase 3 INDIGO data showing a 56% reduction in flare risk versus placebo over 52 weeks .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLcclrKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667415","title":"Zenas Biopharma Announces Submission of Biologics License Application (Bla) to U.S. FDA for Obexelimab in Igg4-Rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667415?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:05","pubTimestamp":1779966300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA30HZ1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638301541","title":"What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638301541","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638301541?lang=en_us&edition=fundamental","pubTime":"2026-05-25 00:19","pubTimestamp":1779639554,"startTime":"0","endTime":"0","summary":"Zenas BioPharma recently reported that the first subject has been dosed in a Phase 1 trial of ZB021, an oral small‑molecule IL-17AA/AF inhibitor being tested in healthy volunteers in China in partnership with InnoCare Pharma.\nThis program targets a space where no oral IL-17 inhibitors are currently approved or in late-stage development globally, potentially offering a differentiated option for autoimmune and inflammatory diseases.\nNext, we’ll examine how advancing ZB021 into Phase 1,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/what-zenas-biopharma-zbios-first-in-human-oral-il-17-inhibit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/what-zenas-biopharma-zbios-first-in-human-oral-il-17-inhibit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":0.1137},{"period":"1month","weight":0.1087},{"period":"3month","weight":-0.113},{"period":"6month","weight":-0.4528},{"period":"1year","weight":1.1246},{"period":"ytd","weight":-0.4552}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.1514},{"period":"6month","weight":0.0972},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Zenas BioPharma Inc.(ZBIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}